Marty Makary

And if so, what are the priorities for the administration in helping American biotech industry remain competitive?

As you think about those work streams in improving the efficiency, turnaround time, how much can you do this on your own versus how much do you need Congress to act to pass legislation to support those changes?

As you think about those work streams in improving the efficiency, turnaround time, how much can you do this on your own versus how much do you need Congress to act to pass legislation to support those changes?

And are there priorities that you're working with Congress on to try and accelerate drug approval timelines that are necessary?

And are there priorities that you're working with Congress on to try and accelerate drug approval timelines that are necessary?

And going back to this point about cutting down on timelines for phase one, two, three, maybe you can just for the audience that may not work in this industry, very briefly explain phase one, two, three, and then where we think there's the biggest kind of, call it excess regulatory burden that's causing these extended timelines on drug approvals, just to kind of frame it up a little bit.

And going back to this point about cutting down on timelines for phase one, two, three, maybe you can just for the audience that may not work in this industry, very briefly explain phase one, two, three, and then where we think there's the biggest kind of, call it excess regulatory burden that's causing these extended timelines on drug approvals, just to kind of frame it up a little bit.

You're making me sick, because this has always been, from my point of view, one of the most troubling bioethical concerns I've had about the industry, because you don't get a lot of statistical power or benefit from doing this, and it's just awful that we do it.

You're making me sick, because this has always been, from my point of view, one of the most troubling bioethical concerns I've had about the industry, because you don't get a lot of statistical power or benefit from doing this, and it's just awful that we do it.

And if we don't, then we're also putting our industry at risk.

And if we don't, then we're also putting our industry at risk.

So the drug company gets a voucher if they qualify under one of those three criteria and that gives them a fast track?

So the drug company gets a voucher if they qualify under one of those three criteria and that gives them a fast track?

Yeah.

Yeah.

And when will we get a readout on how that program is going and whether it becomes standard?

And when will we get a readout on how that program is going and whether it becomes standard?

Going back to the computational point, we are collecting more data, digitizing that data on patients than ever before.

Going back to the computational point, we are collecting more data, digitizing that data on patients than ever before.

That data should generally be accessible.